| Market Capitalization (Millions $) |
51 |
| Shares
Outstanding (Millions) |
14 |
| Employees |
50 |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-25 |
| Cash Flow (TTM) (Millions $) |
-10 |
| Capital Exp. (TTM) (Millions $) |
0 |
Oncocyte Corporation
Oncocyte Corporation is a healthcare company that specializes in the development of diagnostic tests for cancer. The company focuses on utilizing advanced molecular diagnostics to detect and analyze cancer cells in order to provide more accurate diagnosis and personalized treatment options for cancer patients.
Oncocyte Corporation's primary product is the DetermaRx test, which is used to determine the risk of cancer recurrence in early-stage lung cancer patients. The test analyzes the patient's tumor biology and provides information on the likelihood of their cancer returning after surgery. This can help guide treatment decisions and potentially improve patient outcomes.
In addition to the DetermaRx test, Oncocyte Corporation is also working on developing other diagnostic tests for lung, breast, and bladder cancer. These tests aim to provide clinicians with better tools for early detection, prognosis, and therapeutic guidance.
The company collaborates with academic institutions, research organizations, and healthcare practitioners to advance their diagnostic technologies. They are committed to improving patient care by providing accurate and reliable diagnostic tools that enable personalized treatment approaches in the fight against cancer.
Company Address: 15 Cushing Irvine 92618 CA
Company Phone Number: 409-7600 Stock Exchange / Ticker: NASDAQ OCX
|
4.9% 
100 %